期刊文献+

脾边缘带淋巴瘤3例报告及文献复习 被引量:3

Three case reports of splenic marginal zone lymphoma and literature review
下载PDF
导出
摘要 目的总结脾边缘带淋巴瘤的临床特点、组织病理学特征、诊断、治疗方法及预后。方法回顾分析我院3例脾边缘带淋巴瘤患者的临床和随诊资料,并对相关文献进行复习。结果3例患者发病年龄49~71岁,从出现症状到明确诊断时间为3~11个月。3例发病时均有脾大,1例出现脾功能亢进造成的全血细胞减少,2例出现发热等B组症状,2例有结外受累。3例均为脾切除后经病理明确诊断,2例化疗后随诊仍为完全缓解,1例化疗结束后10个月复发。结论脾边缘带淋巴瘤是一种惰性的淋巴增殖性疾病,中位生存期长,65%~78%患者的诊断后生存期可超过5年,故明确诊断后可采用相对保守的治疗措施。 Objective To investigate the clinical and histological characteristics, the diagnosis, treatment and prognosis of splenic marginal zone lymphoma. Methods Three cases of splenic marginal zone lymphoma were included and analyzed retrospectively. The related literature about splenic marginal zone lymphoma were reviewed. Results The age of three patients were from 49 to 71 years old. The interval between symptom appearance and diagnosis ranged from 3 to 11 months. All of the three cases have splenomegaly, but only one has cytopenias. Symptom B and involvement outside lymph nodes were both detected in two cases. The diagnosis of three cases were made after splenectomy. After chemical therapy, two cases were still in complete remission, but 1 case relapsed 10 months later. Conclusions Splenic marginal zone lymphoma is a low-grade lymphoma with an indolent clinical course and a long median survival time. About two thirds patients can survive more than 5 years after diagnosis. So relatively conservative therapy is appreciated.
出处 《北京医学》 CAS 2008年第2期74-77,共4页 Beijing Medical Journal
关键词 脾边缘带淋巴瘤 脾切除 临床特点 组织病理学特征 诊断 治疗 预后 Splenic marginal zone lymphoma Splenectomy
  • 相关文献

参考文献11

  • 1Schmid C, Kirkham N, Diss T, et al. Splenic marginal zone cell lymphoma. Am J Surg Pathol, 1992, 16:455 - 466.
  • 2Isaacson PG, Piris MA, Catovski D, et al. Splenic marginal zone lymphoma. Jaffe ES, Harris NL, Stein H, et al. Tumors of haematopoietic and lymphoid tissues. WHO Classification of Tumors.Lyon: IARC Press, 2001 : 135 - 137.
  • 3Lannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes-Hematologic findings and outcomes in a series of 57 patients. Cancer, 2004,101:2050 - 2057.
  • 4Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002, 100:1648 - 1654.
  • 5Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma; an analysis of 81 patients. Clin lymphoma, 2002, 3:41 - 47.
  • 6Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer, 2004, 110:380-385.
  • 7sMateo M, Mollejo M, Villuendas R, et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol, 1999, 154:1583- 1589.
  • 8Thieblemont C, Coiffer B. Management of marginal zone lymphomas. Curr Treat Options Oncol, 2006, 7:213 - 222.
  • 9Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherary alone. Cancer, 2006, 107:125 - 135.
  • 10Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematolygica, 2005, 90:856- 858.

同被引文献28

  • 1陈辉树,刘恩彬,李占琦,杨晴英,方立环,徐茂强,罗彦英,康永录,曹鹏飞.46例脾脏淋巴组织肿瘤病理形态免疫表型及分子遗传学探讨[J].中国肿瘤临床,2005,32(12):700-705. 被引量:10
  • 2Inarndar KV,Medeiros LJ,Jorgensen JL,et al.Bone marrow involvement by marginal zone B-cell lymphomas of different types.Am J Clin Pathol,2008,129(5):714-722.
  • 3Swerdow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon ; 2008.
  • 4Chac6n JI, Mollejo M, Mu:oz E, et al. Splenic marginal zone lym- phoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002 ; 100(5 ) : 1648 - 1654.
  • 5Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood, 2006;107 (12) :4643 -4649.
  • 6Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in pa- tients with splenic marginal zone lymphoma and marginal zone lym- phoma treated with rituximab with or without ehemotherapy or chemo- therapy alone. Cancer, 2006 ; 107 ( 1 ) : 125 - 135.
  • 7Salido M, Bar6 C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lym- phomas : a multicenter study of the Splenic B-Cell Lymphoma Group. Blood, 2010;116(9) :1479 - 1488.
  • 8Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and thera- peutic criteria. Leukemia, 2008 ;22 ( 3 ) :487 - 495.
  • 9Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with vil- lous lymphocytes, associated with type II cryoglobulinemia and HCV infection : a new entity? Blood, 2005 ; 105 ( 1 ) :74 - 76.
  • 10Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus sero- prevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer, 2004 ; 100 ( 1 ) : 107 - 115.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部